Navigation Links
Southern Research Scientists to Present New Data at the American Association for Cancer Research 102nd Annual Meeting in Orlando

BIRMINGHAM., Ala., March 29, 2011 /PRNewswire-USNewswire/ -- Southern Research Institute, a not-for-profit organization that conducts basic and applied research in the areas of preclinical drug discovery and drug development today announced that its scientists will be delivering 13 poster presentations at the AACR 102nd Annual Meeting 2011, April 2-6, in Orlando, Fla. Southern Research will also be available to meet with scientists at Booth #543.

Southern Research has discovered more than 20 anti-cancer drugs which have been accepted into clinical trials. Of those, seven have received FDA approval, with six additional drugs currently in late stage preclinical and early clinical trials. Further, Southern Research has evaluated 50 percent of all other FDA-approved cancer drugs on the market. Contract research services include basic research and target identification, lead discovery and optimization, preclinical development and clinical trials support.

Southern Research scientists will present new preclinical data posters in the Exhibit Hall:

Sunday April 3, 2011

1:00 p.m. – 5:00 p.m.

#837:  Novel sulindac derivatives that inhibit colon cancer growth by a cyclooxygenase-independent mechanism involving PDE5 inhibition and the suppression of nuclear Beta-catenin levels   (Exhibit Hall A4-C, Poster Section 34)

Monday April 4, 2011

8:00 a.m. – 12:00 p.m.

#1053:  Mouse Kremen 1 negatively regulates Wnt/Beta-catenin signaling in human breast cancer MDA-MB-231 cells   (Exhibit Hall A4-C, Poster Section 3)

#1853: PDE5 suppression selectively induces apoptosis of human breast tumor cells and attenuates Wnt/Beta-catenin mediated transcription   (Exhibit Hall A4-C, Poster Section 34)

#1865:  Colon cancer chemopreventive properties of a non-cyclooxygenase inhibitory amide derivative of sulindac   (Exhibit Hall A4-C, Poster Section 34)

1:00 p.m. – 5:00 p.m.

#2537:  Novel 2'-deoxycytidine analogs as DNA demethylation agents (Exhibit Hall A4-C, Poster Section 26)

Tuesday April 5, 2011

8:00 a.m. – 12:00 p.m.

#3114:  Effects of tumor-stromal interactions on gene expression in panel of mouse tumor models   (Exhibit Hall A4-C, Poster Section 11)

#3707:  Sulindac sulfide inhibits growth and induces apoptosis of human colon tumor cells by a cGMP-dependent pathway leading to suppression of Beta-catenin transcription activity (Exhibit Hall A4-C, Poster Section 34)

1:00 p.m. – 5:00 p.m.

#4418:  Affymetrix whole genome microarray analysis of 24 human tumor xenograft models and the cell lines from which they were developed: Clustering of targets vs tumor tissue of origin   (Exhibit Hall A4-C, Poster Section 24)

#4265: Bithionol as an inhibitor of tumor angiogenesis (Exhibit Hall A4-C, Poster Section 18)

#3943:  Affymetrix whole genome microarray analysis of 51 human tumor cell lines representative of 16 different tissues of origin: Unsupervised hierarchical clustering

(Exhibit Hall A4-C, Poster Section 6)

#4610:  NO-NSAIDs inhibit colon tumor cell growth by a cGMP-independent mechanism (Exhibit Hall A4-C, Poster Section 33)

Wednesday April 6, 2011

8:00 a.m. – 12:00 p.m.

#5443:  A novel biosensor for monitoring intracellular cGMP in live cells (Exhibit Hall A4-C, Poster Section 29)

#5154: Serotonin signaling as a novel target of tumor angiogenesis (Exhibit Hall A4-C, Poster Section 18)

Southern Research will also have members of its new preclinical, non-invasive imaging team at Booth #543 on hand to discuss this new service.


Southern Research Institute, founded in 1941, is an independent non-profit organization conducting basic and applied research and development.  More than 530 employees support commercial and government clients and partners in the pharmaceutical, biotechnology, defense, aerospace, environmental and energy sectors through technology out-licensing, sponsored research, and strategic collaborations.  Headquartered in Birmingham, Ala., Southern Research has facilities in Wilsonville, Ala., Frederick, Md., and Durham, NC and offices in Huntsville, Ala., New Orleans, La., Washington, DC and Kiev, Ukraine. For more information about our capabilities, contact us by email at or call 888-322-1166 (U.S.) or 1-205-581-2830 (International.)

Contact: Rhonda Jung

SOURCE Southern Research Institute
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Southern Home Medical Equipment Appoints Jerry Overcash to the Board of Directors
2. Southern Home Medical Equipment Engages Northern Virginia Based Waterford Holdings Group to Evaluate and Consider Acquisition Candidates in the Mid-Atlantic Area
3. Encinitas Nursing and Rehabilitation Center First in Southern California to Deploy Voice Technology for Outcomes-Based Care
4. MinuteClinic and St. Rose Dominican Hospitals Form Clinical Collaboration to Improve Access to Health Care in Southern Nevada
5. BioSpace Showcases Southern Californias Growing Life Science Region
6. Southern Research Announces Completion of $20 Million Bond Transaction
7. Southern California Cell Company Partners With Northern California Life Science Research Technology Company for Developing Human Derived Disease Specific iPS Cell Lines
8. Pro Medicus/Visage Imaging Signs Deal with Sydney-based Southern Radiology
9. Jubilant Organosys, UAB and Southern Research Enter Into Drug Discovery Joint Venture
10. Diplomat Specialty Pharmacy Continues to Expand - Opens Location in Southern California
11. Partnership for Prescription Assistance Prepared to Help Southern Workers Hurt by Recession
Post Your Comments:
(Date:9/27/2017)... their devotion to personalized service, SMP Pharmacy Solutions announces their ... South Florida Business Journal,s 50 Fastest-Growing Companies, and listed for ... specialty pharmacy has found its niche.  To that end, the ... by SFBJ as the 2017 Power Leader in Health Care. ... award in October, Bardisa said of the three achievements, "It,s ...
(Date:9/23/2017)... -- Janssen Biotech, Inc. (Janssen) announced today that it ... Food and Drug Administration (FDA) for the Biologics License ... of moderately to severely active rheumatoid arthritis (RA). The ... to further evaluate the safety of sirukumab in the ... "We are disappointed by ...
(Date:9/19/2017)... --  ZirMed Inc ., a recognized leader in cloud-based revenue ... been ranked #1 by its users for the seventh consecutive ... Survey. ZirMed was recognized as the top-ranked end-to-end revenue cycle ... over 200 beds and holds one of the longest #1 ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian ... On The Brink” is the creation of published author, William Nowers. Captain Nowers ... a WWII veteran, he spent thirty years in the Navy. Following his career ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 million ... by frequent cessation in breathing. Oral appliances can offer significant relief to about ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... to meet the demand of today’s consumer and regulatory authorities worldwide. From Children’s ... experts and tested to meet the highest standard. , These products are ...
(Date:10/12/2017)... Bethesda, MD (PRWEB) , ... October 12, 2017 , ... ... Award of Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s ... 4 – 8. , In honor of Morris F. Collen, a pioneer in the ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... system that we intend to develop to enable prevention of a major side ... severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA ...
Breaking Medicine News(10 mins):